The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Therapeutic targeting of splicing factor mutations in myeloid malignancies
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential therapeutic targeting of splicing factor mutations in myeloid malignancies. He explains that targeting the wild-type splicing factor can kill leukemia cells. Although current preclinical trials with two agents have been unsuccessful, Dr Stein emphasizes that these failures provide valuable insights for future success. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
